CD79A and metabolic syndrome: After further adjusting for multiple confounders (Model 2: age, gender, smoking and a diagnosis of metabolic syndrome; Model 3: Model 2 and additionally biological (adalimumab) therapy), a similar trend was observed between IHS4 scale and IgG levels, but not for IgM and IgA classes.